CTOs on the Move

Ecovative Design

www.ecovativedesign.com

 
Ecovative uses biology to solve fundamental human needs at industrial scales and in consumer applications. Ecovative uses mycelium to grow category defining products ranging from leather like textiles to sustainable packaging to high performance foams for apparel and beauty.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ecovative Design raised $10M on 10/11/2019

Similar Companies

Exagen Diagnostics Inc.

Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Main OfficeReaction Design

Main OfficeReaction Design is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenSpera

GenSpera, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quentis Therapeutics

Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.

Seattle Genetics

Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.